Reading Time: 6 minutes Politicians have to stop creating impediments to access
Author: Nigel Rawson
Dr. Nigel Rawson is a pharmacoepidemiologist, pharmaceutical policy researcher, and President of Eastlake Research Group in Oakville, Ontario. Educated in the United Kingdom, he holds an MSc in statistics and a PhD in pharmacoepidemiology. Dr. Rawson has performed epidemiologic studies of the use of drugs and their outcomes for over 35 years and published more than 120 book chapters and articles in peer-reviewed journals.
Gene therapy appraisals may limit new drugs in Canada
Reading Time: 3 minutes Canada’s separate environmental protection oversight unnecessarily delays development and approval
Denying hope and health to Canadians with rare disorders
Reading Time: 3 minutes Manufacturers must overcome several federal government hurdles before patients have access to drugs
Ottawa blocking Canadians’ access to innovative drugs
Reading Time: 3 minutes Health Canada’s revisions to the drug-pricing review board will delay or prevent access to new drugs
Proposed changes could reduce access to prescription drugs
Reading Time: 4 minutes While well-intentioned, changes to Patented Medicine Prices Review Board could stop companies from launching new drugs
When it comes to pharmacare, be careful what you wish for
Reading Time: 3 minutes Provincial governments are more interested in restricting access than in creating better programs